anti-ITGB1 antibody

Anti-ITGB1 antibody refers to a class of monoclonal antibodies designed to target and inhibit integrin beta-1 (ITGB1), also known as CD29. ITGB1 is a key cell surface receptor that mediates cell-extracellular matrix adhesion and downstream signaling pathways involved in cell migration, survival, and proliferation. In H3K27M-mutant diffuse midline gliomas (DMG), ITGB1 expression is associated with higher tumor grade and poor prognosis. Inhibition of ITGB1 has been shown to disrupt tumor cell migration, reduce MYC-driven purine biosynthesis, and decrease the stemness of glioma cells. Preclinical studies, particularly those involving CNS-directed delivery, have demonstrated that anti-ITGB1 antibodies can extend survival in DMG models, especially when used in combination with inhibitors of other integrins (such as ITGB3 and ITGB5) to prevent compensatory signaling.

Other names

integrin beta-1 antibodyanti-CD29 antibodyanti-CD-29 antibodyanti-CD 29 antibody